CNS Pharmaceuticals Inc - CNSP Net earnings per share (EPS TTM)

Public company logo of CNS Pharma (CNSP)

CNS Pharmaceuticals is developing breakthrough treatments to overcome CNS barriers for the treatment of brain tumors. However, the lack of profitability and a heavy reliance on a single Phase 2 trial create significant risks. A competitive advantage is provided by the molecule's high permeability, which is confirmed by the EPS YoY TTM chart. The value of 68.40 serves as the final mark for this metric.

CNSP CNS Pharmaceuticals Inc: Earnings per share for the last twelve months in the range 02/11/2024 - 11/18/2026

CNSP (CNS Pharmaceuticals, Inc.): analytical breakdowns and indicator data

Initial company analysis:CNSP (CNS Pharma)
Manufactured product of cnspharma.com

A fundamental valuation of CNS Pharmaceuticals (CNSP) requires an analysis of actual earnings per share dynamics. This metric measures the percentage change in trailing twelve-month (TTM) income, revealing the sustainability of the business's profitability trend. By analyzing the annual EPS TTM growth rate, an investor can discern the pace of net income capitalization. For a biotech firm focused on single tests for brain cancer, the volatility of this line reflects the risks associated with preclinical expenditures. Sharp fluctuations in this indicator signal the critical impact of research and development costs.